Live Breaking News & Updates on Revised january

Stay updated with breaking news from Revised january. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the...

United-states , South-san-francisco , California , Georgia , American , David-rosen , Jorgee-cortes , Raul-rodriguez , Cecilf-whitaker-jr , Rigel-pharmaceuticals-inc , American-cancer-society , European-medicines-agency

Assessment-Guided Interventions for Elderly Multiple Myeloma Patients Highlight Benefit of Oncology Pharmacists

Patients readily accepted physical interventions and referrals to oncology clinical pharmacy practitioners.

United-states , American , National-organization-for-rare-disorders , University-of-north-carolina-at-chapel-hill , American-cancer-society , Minerva-studios , North-carolina , Chapel-hill , Rare-disorders , Updated-february , Revised-january

Rigel Pharmaceuticals Provides Business Update

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter of 2023,...

South-san-francisco , California , United-states , Texas , American , David-rosen , Raul-rodriguez , Kissei-pharmaceutical-co-ltd , Exchange-commission , European-medicines-agency , Prnewswire-rigel-pharmaceuticals-inc , American-society-of-hematology-annual-meeting

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial...

California , United-states , Japan , Georgia , San-diego-convention-center , Texas , Houston , South-san-francisco , San-diego , Japanese , American , Jorgee-cortes

U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1

14.10.2023 - Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or ...

United-states , Taiwan , United-kingdom , Japan , South-korea , Edinburgh , City-of , American , Scotland , Catherine-owen , Johnm-kirkwood , Bristol-myers-squibb

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1

In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1

CheckMate -76K marks the fifth Opdivo-based...

Japan , South-korea , United-kingdom , Taiwan , Edinburgh , City-of , United-states , Scotland , American , Johnm-kirkwood , Bristol-myers-squibb , Catherine-owen

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma¹

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma¹
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Edinburgh , City-of , United-kingdom , South-korea , Taiwan , Japan , American , Scotland , Catherine-owen , Johnm-kirkwood , Bristol-myers-squibb

ASCO 2023: Solid Tumors

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

United-states , Japan , Australia , University-of-chicago , Illinois , Germany , New-haven , Connecticut , China , Peking , Beijing , California

New Federal Laws Now In Effect: Pregnant Workers Fairness Act (PWFA) and Providing Urgent Maternal Protections for Nursing Mothers Act (PUMP) | Goldberg Segalla

Key Takeaways - The PWFA creates a new avenue for pregnant employees to request reasonable accommodations not previously provided under the ADA, PDA or FMLA.

United-states , Americans , Goldberg-segalla , Employment-opportunity-commission , Department-of-labor , Us-equal-employment-opportunity-commission , Pregnant-workers-fairness-act , Should-know-about , Employment-opportunity , Disabilities-act , Pregnancy-discrimination-act , Medical-leave-act

Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®...

United-states , California , Georgia , South-san-francisco , American , Jorgee-cortes , Cecilf-whitaker-jr , David-rosen , Raul-rodriguez , Exchange-commission , Drug-administration , American-cancer-society